Late phase transfusion after CAR T therapy is associated with persistent hematotoxicity and non-relapse mortality in multiple myeloma: a post hoc analysis - PubMed
4 hours ago
- #transfusion outcomes
- #multiple myeloma
- #CAR T therapy
- CAR T therapy in relapsed/refractory multiple myeloma often leads to transfusion needs, studied in 155 patients.
- Late transfusion (>30 days post-treatment) correlates with worse survival: median overall survival drops from 37.87 to 10.87 months.
- Early transfusion (≤30 days) is linked to acute inflammation but shows limited impact on survival outcomes.
- Late transfusion also associates with shallower treatment response and higher non-relapse mortality rates.
- Reducing transfusion requirements may improve patient outcomes and reduce mortality in multiple myeloma post-CAR T therapy.